| For: | Guo Y, Yu XR, Gu HD, Wang YJ, Yang ZG, Chi JF, Zhang LP, Lin H. Farrerol ameliorates diabetic cardiomyopathy by inhibiting ferroptosis via miR-29b-3p/SIRT1 signaling pathway in endothelial cells. World J Diabetes 2025; 16(9): 109553 [PMID: 40980297 DOI: 10.4239/wjd.v16.i9.109553] |
|---|---|
| URL: | https://www.wjgnet.com/1948-9358/full/v16/i9/109553.htm |
| Number | Citing Articles |
| 1 |
Xiaofang Zhang, Hui Lin, Xinrou Yu, Tiantian Lu, Jun Wang, Hui Ji, Dihua Huang, Dajun Lou. Targeting SIRT3 in Diabetic Cardiomyopathy: Mechanism-Based Therapeutic Strategies. Cardiovascular Drugs and Therapy 2026; doi: 10.1007/s10557-026-07843-0
|
| 2 |
Chizurum Philip Ikegbuna, Elodie Sepde Mbwanzuh Tompene, Ebube Favour Edwin, Mmesoma Ruth Ikegbuna. Targeted therapeutic management of diabetes using phytoconstituents: molecular mechanisms, evidence map (2015–2025), and translational outlook. Exploration of Drug Science 2026; 4 doi: 10.37349/eds.2026.1008139
|
| 3 |
Javier Donate-Correa, Carlos E Martínez-Alberto. Farrerol and the miR-29b-3p/sirtuin 1 pathway: A mechanistic breakthrough in protecting the diabetic heart. World Journal of Diabetes 2026; 17(2): 113221 doi: 10.4239/wjd.v17.i2.113221
|
